Hans van Houte, Chief Financial Officer at Nurix Therapeutics, Inc. (NRIX), sold 7,322 shares at $16.58 ($122K) on 2026-01-30, disclosed to the SEC on 2026-01-30.
Open-market sale of $122k NRIX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.58 | 3,588 | $59K | 49.0% |
| 2 | $16.58 | 3,588 | $59K | 49.0% |
| 3 | $17.37 | 73 | $1K | 1.0% |
| 4 | $17.37 | 73 | $1K | 1.0% |
| Total | $16.60 avg | 7,322 | $122K | 100% |
| Filing → |
| NRIX | SELL | 2026-05-05 | $233K | — | Filing → |
| NRIX | SELL | 2026-04-30 | $40K | — | Filing → |
| NRIX | SELL | 2025-11-03 | $158K | — | Filing → |